SKP2 promotes breast cancer tumorigenesis and radiation tolerance through PDCD4 ubiquitination

• Published in: Journal of experimental & clinical cancer research Vol. 38; no. 1; pp. 76 - 15
• Main Authors: Li, Ce, Du, Lutao, Ren, Yidan, Liu, Xiaoyan, Jiao, Qinlian, Cui, Donghai, Wen, Mingxin, Wang, Chuanxin, Wei, Guangwei, Wang, Yunshan, Ji, Aiguo, Wang, Qin
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 13.02.2019; BioMed Central; BMC
• Subjects: Adjuvant chemotherapy; Analysis; Apoptosis; Biochemistry; Breast cancer; Cancer cells; Cancer prevention; Cancer therapies; Cancer treatment; Cell adhesion & migration; Cell apoptosis; Cell cycle; Cell death; Cell growth; Deoxyribonucleic acid; DNA; DNA damage; DNA repair; DNA-damage response; Genes; Health aspects; Kinases; Mass spectrometry; PDCD4; Phosphorylation; Plasmids; Prostate cancer; Proteins; Radiation (Physics); Radiation therapy; Radiotherapy; Signal transduction; SKP2; Tumor proteins; Tumorigenesis; Tumors; Ubiquitin; PDCD4; DNA-damage response; Breast cancer; Radiotherapy; SKP2; Cell apoptosis
• ISSN: 1756-9966; 0392-9078; 1756-9966
• DOI: 10.1186/s13046-019-1069-3

S-phase kinase-associated protein 2 (SKP2) is an oncogene and cell cycle regulator that specifically recognizes phosphorylated cell cycle regulator proteins and mediates their ubiquitination. Programmed cell death protein 4 (PDCD4) is a tumor suppressor gene that plays a role in cell apoptosis and DNA-damage response via interacting with eukaryotic initiation factor-4A (eIF4A) and P53. Previous research showed SKP2 may interact with PDCD4, however the relationship between SKP2 and PDCD4 is unclear. To validate the interaction between SKP2 and PDCD4, mass spectrometric analysis and reciprocal co-immunoprecipitation (Co-IP) experiments were performed. SKP2 stably overexpressed or knockdown breast cancer cell lines were established and western blot was used to detect proteins changes before and after radiation. In vitro and in vivo experiments were performed to verify whether SKP2 inhibits cell apoptosis and promotes DNA-damage response via PDCD4 suppression. SMIP004 was used to test the effect of radiotherapy combined with SKP2 inhibitor. We found that SKP2 remarkably promoted PDCD4 phosphorylation, ubiquitination and degradation. SKP2 promoted cell proliferation, inhibited cell apoptosis and enhanced the response to DNA-damage via PDCD4 suppression in breast cancer. SKP2 and PDCD4 showed negative correlation in human breast cancer tissues. Radiotherapy combine with SKP2 inhibitor SMIP004 showed significant inhibitory effects on breast cancer cells in vitro and in vivo. We identify PDCD4 as an important ubiquitination substrate of SKP2. SKP2 promotes breast cancer tumorigenesis and radiation tolerance via PDCD4 degradation. Radiotherapy combine with SKP2-targeted adjuvant therapy may improve breast cancer patient survival in clinical medicine.